2025 Global Report For In-Vivo CAR Cell Therapy

In-vivo CAR (Chimeric Antigen Receptor) therapies are redefining immunotherapy by reprogramming T cells directly inside the patient, removing the need for cell extraction or complex laboratory processing. This approach promises scalable, ready-to-use treatments that could overcome the high costs, manufacturing bottlenecks, and limited patient access seen with conventional CAR-T therapies—barriers that left most eligible lymphoma patients untreated in 2022.

Rapid advancements in delivery technologies, including lipid nanoparticle (LNP) systems, viral vectors, and mRNA platforms, have fueled unprecedented growth in the in-vivo CAR pipeline. Between 2020 and 2024, the number of active assets expanded more than tenfold, with global investment surpassing $2 billion. The momentum is set to continue, with projections exceeding 100 publicly disclosed programs by the close of 2025. This surge is matched by increasing clinical activity, including the first human trials in 2025 and strategic collaborations between major players such as AbbVie with Umoja and AstraZeneca with EsoBiotec, positioning in-vivo CAR therapies at the forefront of oncology and autoimmune innovation.